The weight of human leukocyte antigen (HLA) matching in kidney allocation algorithms,
especially in the United States, has been devalued in a stepwise manner, supported by the …

Antibody-mediated rejection (ABMR) in organ transplantation has been recognized as the
main cause of graft rejection. Binding of donor-specific HLA antibody (DSA) and A/B blood …

Follicular helper T (Tfh) cells have been implicated in controlling rejection after allogeneic
kidney transplantation, but the precise subsets, origins, and functions of Tfh cells in this …

Our understanding of the role of B cells in organ transplantation remains incomplete and
continues to grow. The majority of research has focused on the detrimental role of antibodies …

Recent adjustments to the histological diagnosis and the introduction of molecular
classification are providing renewed support for the paradigm that antibody‐mediated …

The ability to personalize management for a given kidney transplant recipient and identify
treatments that will improve their long-term outcome remains a critical unmet need. Earlier …

In kidney transplantation, eplet mismatches between donor and recipient have been
associated with de novo donor-specific antibody development. Eplets are theoretically …

Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy has revolutionized the
treatment of various diseases, including cancers and autoimmune disorders. However, all …

Antibody-mediated rejection (ABMR) is associated with poor transplant outcomes and was
identified as a leading cause of graft failure after kidney transplantation. Although the …

Background The quantification of rejection treatment efficacy has been insufficient using
traditional markers due, in part, to the lagging response of serum creatinine and histologic …